Immune mechanisms and the impact of the disrupted lung microbiome in chronic bacterial lung infection and bronchiectasis

Clinical and Experimental Immunology

Volumn 171, Issue 2, 2013, Pages 117-123

  Boyton, R J ^a,b   Reynolds, C J ^a   Quigley, K J ^a   Altmann, D M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Bronchiectasis; Infection; Lung immunology; Microbiome; NK cell

Indexed keywords

ETANERCEPT; HLA C ANTIGEN; INFLIXIMAB; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; NATURAL KILLER CELL RECEPTOR;

ANTIBIOTIC THERAPY; ARTICLE; AUTOIMMUNITY; BRONCHIECTASIS; CELL ACTIVATION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HOMOZYGOSITY; HUMAN; IMMUNE DEFICIENCY; IMMUNOGENETICS; LUNG INFECTION; MICROBIAL COMMUNITY; MICROBIOME; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS;

ANIMALS; BACTERIAL INFECTIONS; BRONCHIECTASIS; CD4-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; GENETIC PREDISPOSITION TO DISEASE; HLA-C ANTIGENS; HUMANS; KILLER CELLS, NATURAL; LUNG; LUNG DISEASES; METAGENOME; MICROBIAL CONSORTIA; POLYMORPHISM, GENETIC; RECEPTORS, KIR;

EID: 84872164457     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12003     Document Type: Article

References (44)

1. Boyton RJ, Openshaw PJ. Pulmonary defences to acute respiratory infection. Br Med Bull 2002; 61:1-12.
2. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 2012; 486:207-14.
3. Boyton RJ. Bronchiectasis. Medicine 2012; 40:267-72.
4. Cole P. A new look at the pathogenesis and management of persistent bronchial sepsis: a 'vicious circle' hypothesis and its logical therapeutical connotations. Strategies for the management of chronic bronchial sepsis. In: Davies RJ, ed. Oxford: The Medicine Publishing Foundation, 1984; 1-20.
5. Gadola SD, Moins-Teisserenc HT, Trowsdale J, Gross WL, Cerundolo V. TAP deficiency syndrome. Clin Exp Immunol 2000; 121:173-8.
6. Chang AB, Grimwood K, Mulholland EK, Torzillo PJ. Working group on indigenous paediatric respiratory health. Bronchiectasis in indigenous children in remote Australian communities. Med J Aust 2002; 177:200-4.
7. Einsiedel L, Fernandes L, Spelman T, Steinfort D, Gotuzzo E. Bronchiectasis is associated with human T-lymphotropic virus 1 infection in an Indigenous Australian population. Clin Infect Dis 2012; 54:43-50.
8. Afzelius BA. A human syndrome caused by immotile cilia. Science 1976; 193:317-9.
9. Boyton RJ, Smith J, Jones M et al. Human leucocyte antigen class II association in idiopathic bronchiectasis, a disease of chronic lung infection, implicates a role for adaptive immunity. Clin Exp Immunol 2008; 152:95-101.
10. Reynolds C, Ozerovitch L, Wilson R, Altmann D, Boyton R. Tolllike receptors 2 and 4 and innate immunity in neutrophilic asthma and idiopathic bronchiectasis. Thorax 2007; 62:279.
11. Seitz AE, Olivier KN, Steiner CA, Montes de Oca R, Holland SM, Prevots DR. Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006. Chest 2010; 138:944-9.
12. Cohen M, Sahn SA. Bronchiectasis in systemic diseases. Chest 1999; 116:1063-74.
13. Eaton TE, Lambie N, Wells AU. Bronchiectasis following colectomy for Crohn's disease. Thorax 1998; 53:529-31.
14. Gregersen S, Aaløkken TM, Mynarek G et al. High resolution computed tomography and pulmonary function in common variable immunodeficiency. Respir Med 2009; 103:873-80.
15. Boyton RJ, Reynolds C, Wahid FN et al. IFN gamma and CXCR-1 gene polymorphisms in idiopathic bronchiectasis. Tissue Antigens 2006; 68:325-30.
16. Lieberman-Maran L, Orzano IM, Passero MA, Lally EV. Bronchiectasis in rheumatoid arthritis: report of four cases and a review of the literature - implications for management with biologic response modifiers. Semin Arthritis Rheum 2006; 35:379-87.
17. Esaki T, Sugimoto M, Mori S, Yamashita A, Matsumoto M, Kohrogi H. A case of pulmonary nontuberculous mycobacteriosis aggravated during treatment with etanercept for rheumatoid arthritis. Nihon Kokyuki Gakkai Zasshi 2010; 48:312-6.
18. Beck JM, Young VB, Huffnagle GB. The microbiome of the lung. Transl Res 2012; 160:258-66.
19. Zhao J, Schloss PD, Kalikin LM et al. Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci USA 2012; 109:5809-14.
20. Sze MA, Dimitriu PA, Hayashi S et al. The lung tissue microbiome in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 185:1073-80.
21. Han MK, Huang YJ, Lipuma JJ et al. Significance of the microbiome in obstructive lung disease. Thorax 2012; 67:456-63.
22. Honda K, Littman DR. The microbiome in infectious disease and inflammation. Ann Rev Immunol 2012; 30:759-95.
23. Blaser MJ, Falkow S. What are the consequences of the disappearing human microbiota? Nat Rev Microbiol 2009; 7:887-94.
24. Ivanov II, Littman DR. Modulation of immune homeostasis by commensal bacteria. Curr Opin Microbiol 2011; 14:106-14.
25. Olszak T, An D, Zeissig S et al. Microbial exposure during early life has persistent effects on natural killer T cell function. Science 2012; 336:489-93.
26. Relman DA. Microbial genomics and infectious diseases. N Engl J Med 2011; 365:347-57.
27. Peterson DA, Frank DN, Pace NR, Gordon JI. Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. Cell Host Microbe 2008; 3:417-27.
28. Silva JR, Jones JA, Cole PJ, Poulter LW. The immunological component of the cellular inflammatory infiltrate in bronchiectasis. Thorax 1989; 44:668-73.
29. Curtis MM, Way SS. Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens. Immunology 2009; 126:177-85.
30. Aujla SJ, Dubin PJ, Kolls JK. Th17 cells and mucosal host defense. Semin Immunol 2007; 19:377-82.
31. Tan HL, Regamey N, Brown S, Bush A, Lloyd CM, Davies JC. The Th17 pathway in cystic fibrosis lung disease. Am J Respir Crit Care Med 2011; 184:252-8.
32. King PT, Ngui J, Gunawardena D, Holmes PW, Farmer MW, Holdsworth SR. Systemic humoral immunity to non-typeable Haemophilus influenzae. Clin Exp Immunol 2008; 153 :376-84.
33. King PT, Ngui J, Farmer MW, Hutchinson P, Holmes PW, Holdsworth SR. Cytotoxic T lymphocyte and natural killer cell responses to non-typeable Haemophilus influenzae. Clin Exp Immunol 2008; 152:542-51.
34. Boyton RJ, Altmann DM. Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in disease. Clin Exp Immunol 2007; 149:1-8.
35. Cheent K, Khakoo SI. Natural killer cells: integrating diversity with function. Immunology 2009; 126:449-57.
36. Khakoo SI, Carrington M. KIR and disease: a model system or system of models? Immunol Rev 2006; 214:186-201.
37. Boyton RJ, Smith J, Ward R et al. HLA-C and killer cell immunoglobulin-like receptor genes in idiopathic bronchiectasis. Am J Respir Crit Care Med 2006; 173:327-33.
38. Boyton RJ. Regulation of immunity in bronchiectasis. Med Mycol 2009; 47 (Suppl. 1):S175-82.
39. Martin MP, Nelson G, Lee JH et al. Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptorgenes in the absence of specific HLA-C alleles. J Immunol 2002;169:2818-22.
40. Nelson GW, Martin MP, Gladman D, Wade J, Trowsdale J, Carrington M. Cutting edge: heterozygote advantage in autoimmune disease: hierarchy of protection/susceptibility conferred by HLA and killer Ig-like receptor combinations in psoriatic arthritis. J Immunol 2004; 173:4273-6.
41. Middleton D, Gonzelez F. The extensive polymorphism of KIR genes. Immunology 2010; 129:8-19.
42. Traherne JA, Martin M, Ward R et al. Mechanisms of copy number variation and hybrid gene formation in the KIR immune gene complex. Hum Mol Genet 2010; 19:737-51.
43. Culley FJ. Natural killer cells in infection and inflammation of the lung. Immunology 2009; 128:151-63.
44. Wesselkamper SC, Eppert BL, Motz GT, Lau GW, Hassett DJ, Borchers MT. NKG2D is critical for NK cell activation in host defense against Pseudomonas aeruginosa respiratory infection. J Immunol 2008; 181:5481-9.